GURUFOCUS.COM » STOCK LIST » USA » NAS » Moderna Inc (NAS:MRNA) » Definitions » Price-to-Free-Cash-Flow
Switch to:

Moderna Price-to-Free-Cash-Flow

: 6.82 (As of Today)
View and export this data going back to 2018. Start your Free Trial

As of today (2022-08-20), Moderna's share price is $146.10. Moderna's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $21.42. Hence, Moderna's Price-to-Free-Cash-Flow Ratio for today is 6.82.

The historical rank and industry rank for Moderna's Price-to-Free-Cash-Flow or its related term are showing as below:

MRNA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.44   Med: 11.45   Max: 86.65
Current: 7.01

During the past 6 years, Moderna's highest Price-to-Free-Cash-Flow Ratio was 86.65. The lowest was 4.44. And the median was 11.45.

MRNA's Price-to-Free-Cash-Flow is ranked better than
85.51% of 207 companies
in the Biotechnology industry
Industry Median: 31.27 vs MRNA: 7.01

Moderna's Free Cash Flow per Share for the three months ended in Jun. 2022 was $0.52. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $21.42.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Moderna was -0.50% per year.


Moderna Price-to-Free-Cash-Flow Historical Data

The historical data trend for Moderna's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Free-Cash-Flow
Premium Member Only - - - 20.32 8.21

Moderna Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.91 14.45 8.21 5.69 6.67

Competitive Comparison

For the Biotechnology subindustry, Moderna's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Moderna Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Moderna's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Moderna's Price-to-Free-Cash-Flow falls into.



Moderna Price-to-Free-Cash-Flow Calculation

Moderna's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=146.10/21.415
=6.82

Moderna's Share Price of today is $146.10.
Moderna's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Moderna  (NAS:MRNA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Moderna Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Moderna's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna Business Description

Moderna logo
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Gomez Jorge M officer: See Remarks C/O DENTSPLY SIRONA INC 13320 BALLANTYNE CORPORATE PLACE CHARLOTTE NC 28277
Burton Paul officer: Chief Medical Officer 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Klinger Shannon Thyme officer: Chief Legal Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Tallett Elizabeth E director 6705 ROCKLEDGE DR SUITE 900 BETHESDA MD 20817
Meline David W officer: Chief Financial Officer 3M COMPANY 3M OFFICE OF GENERAL COUNSEL ST PAUL MN 55144-1000
Horning Sandra director 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Nader Francois director 550 HILLS DRIVE BEDMINSTER NJ 07921
Flagship Venturelabs Iv, Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143
Sagan Paul director AKAMAI TECHNOLOGIES INC 8 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Ruiz Israel director C/O FORTIVE CORPORATION 6920 SEAWAY BOULEVARD EVERETT WA 98203
Zaks Tal Zvi officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Nabel Elizabeth G director BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS ST BOSTON MA 02115
Hoge Stephen officer: President C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Henderson Lori M. officer: General Counsel and Secretary MOLDFLOW CORP 430 BOSTON POST ROAD WAYLAND MA 01778

Moderna Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)